JP2019509063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509063A5 JP2019509063A5 JP2018568183A JP2018568183A JP2019509063A5 JP 2019509063 A5 JP2019509063 A5 JP 2019509063A5 JP 2018568183 A JP2018568183 A JP 2018568183A JP 2018568183 A JP2018568183 A JP 2018568183A JP 2019509063 A5 JP2019509063 A5 JP 2019509063A5
- Authority
- JP
- Japan
- Prior art keywords
- replication
- recombinant retrovirus
- cells
- incompetent recombinant
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001430294 unidentified retrovirus Species 0.000 claims 35
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims 16
- 210000000822 natural killer cell Anatomy 0.000 claims 13
- 230000001589 lymphoproliferative effect Effects 0.000 claims 12
- 230000035897 transcription Effects 0.000 claims 8
- 238000013518 transcription Methods 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 7
- 230000010076 replication Effects 0.000 claims 7
- 230000011664 signaling Effects 0.000 claims 7
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 5
- 239000012528 membrane Substances 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 230000031146 intracellular signal transduction Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000011541 reaction mixture Substances 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 claims 2
- 101710091045 Envelope protein Proteins 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 101710188315 Protein X Proteins 0.000 claims 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000034217 membrane fusion Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 230000026683 transduction Effects 0.000 claims 2
- 238000010361 transduction Methods 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 241000714162 Feline endogenous virus Species 0.000 claims 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 claims 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 claims 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims 1
- 102000004527 Interleukin-21 Receptors Human genes 0.000 claims 1
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 claims 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 101150099493 STAT3 gene Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022062818A JP7474281B2 (ja) | 2016-03-19 | 2022-04-05 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| JP2024064510A JP2024086884A (ja) | 2016-03-19 | 2024-04-12 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662390093P | 2016-03-19 | 2016-03-19 | |
| US62/390,093 | 2016-03-19 | ||
| US201662360041P | 2016-07-08 | 2016-07-08 | |
| US62/360,041 | 2016-07-08 | ||
| US201762467039P | 2017-03-03 | 2017-03-03 | |
| US62/467,039 | 2017-03-03 | ||
| PCT/US2017/023112 WO2017165245A2 (en) | 2016-03-19 | 2017-03-19 | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022062818A Division JP7474281B2 (ja) | 2016-03-19 | 2022-04-05 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019509063A JP2019509063A (ja) | 2019-04-04 |
| JP2019509063A5 true JP2019509063A5 (https=) | 2020-04-30 |
| JP7108551B2 JP7108551B2 (ja) | 2022-07-28 |
Family
ID=58461483
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568183A Active JP7108551B2 (ja) | 2016-03-19 | 2017-03-19 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| JP2022062818A Active JP7474281B2 (ja) | 2016-03-19 | 2022-04-05 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| JP2024064510A Pending JP2024086884A (ja) | 2016-03-19 | 2024-04-12 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022062818A Active JP7474281B2 (ja) | 2016-03-19 | 2022-04-05 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| JP2024064510A Pending JP2024086884A (ja) | 2016-03-19 | 2024-04-12 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10596274B2 (https=) |
| EP (1) | EP3430136A2 (https=) |
| JP (3) | JP7108551B2 (https=) |
| KR (1) | KR102457098B1 (https=) |
| CN (2) | CN116426490A (https=) |
| AU (2) | AU2017236796B2 (https=) |
| CA (1) | CA3017378A1 (https=) |
| CU (1) | CU24649B1 (https=) |
| IL (1) | IL261713B2 (https=) |
| MX (2) | MX2018011345A (https=) |
| RU (1) | RU2755059C2 (https=) |
| SG (2) | SG10202104509PA (https=) |
| WO (1) | WO2017165245A2 (https=) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8450112B2 (en) | 2008-04-09 | 2013-05-28 | Maxcyte, Inc. | Engineering and delivery of therapeutic compositions of freshly isolated cells |
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| EP3365453A2 (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics GmbH | Methods, kits, agents and apparatuses for transduction |
| WO2020047527A2 (en) | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| EP4628587A3 (en) | 2016-04-15 | 2026-02-25 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| SMT202600033T1 (it) | 2016-04-15 | 2026-03-09 | Bioatla Inc | Anticorpi anti-axl, frammenti di anticorpo e loro immunoconiugati e loro utilizzi |
| EP3235908A1 (en) * | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| GB201614093D0 (en) * | 2016-08-17 | 2016-09-28 | Autolus Ltd | Vector |
| KR20230167769A (ko) | 2016-08-26 | 2023-12-11 | 베이롤 칼리지 오브 메드신 | 세포 치료요법을 위한 항상성 활성 사이토킨 수용체 |
| US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| KR20190098747A (ko) * | 2016-12-05 | 2019-08-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료법을 위한 조작된 세포의 제조방법 |
| US20190367876A1 (en) | 2017-01-18 | 2019-12-05 | F1 Oncology, Inc. | Methods of transducing and expanding immune cells and uses thereof |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| WO2018161026A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Il15 compositions and methods for immunotherapy |
| KR102879522B1 (ko) * | 2017-03-03 | 2025-11-04 | 엑수마 바이오테크, 코포레이션 | 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| EP3735460A4 (en) * | 2017-09-18 | 2021-08-11 | Exuma Biotech Corp. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY OF THE LATTER |
| WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
| CA3084551A1 (en) * | 2017-12-14 | 2019-06-20 | Bluebird Bio, Inc. | Daric interleukin receptors |
| EP3735255A4 (en) * | 2018-01-05 | 2021-09-22 | Maxcyte, Inc. | CHRONIC CANCER TREATMENT BY CARS |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| US12312416B2 (en) | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| AU2019222560B2 (en) * | 2018-02-17 | 2025-07-03 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| CN112040986A (zh) | 2018-03-15 | 2020-12-04 | Ksq治疗公司 | 用于改进的免疫疗法的基因调控组合物和方法 |
| CA3096458A1 (en) | 2018-04-12 | 2019-10-17 | Umoja Biopharma, Inc. | Viral vectors and packaging cell lines |
| AU2019250692A1 (en) | 2018-04-13 | 2020-11-05 | Sangamo Therapeutics France | Chimeric antigen receptor specific for Interleukin-23 receptor |
| CN110499291B (zh) * | 2018-05-16 | 2023-11-24 | 上海赛比曼生物科技有限公司 | 无血清培养制备嵌合抗原受体t细胞的方法 |
| JP2021525518A (ja) * | 2018-05-31 | 2021-09-27 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 細胞をゲノム編集及び活性化するための方法 |
| TWI890660B (zh) | 2018-06-13 | 2025-07-21 | 瑞士商諾華公司 | Bcma 嵌合抗原受體及其用途 |
| CN112955174A (zh) | 2018-07-09 | 2021-06-11 | 旗舰先锋创新V股份有限公司 | 融合剂脂质体组合物和其用途 |
| EP4635978A2 (en) * | 2018-08-31 | 2025-10-22 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| CN113840911A (zh) * | 2018-09-02 | 2021-12-24 | 埃克苏马生物技术公司 | 用于在血液中或在富集pbmc中基因修饰淋巴细胞的方法和组合物 |
| EP3864199A4 (en) | 2018-10-08 | 2023-05-03 | Amberstone Biosciences, Inc. | COMPARTMENTAL TESTING FOR BISPECIFIC AND MULTISPECIFIC BIOLOGICALS |
| WO2020092696A1 (en) * | 2018-10-31 | 2020-05-07 | Musc Foundation For Research Development | Ex vivo activation and expansion of t cells for adoptive cell transfer therapy |
| AU2019378883A1 (en) * | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for T cell delivery |
| CN113631718A (zh) * | 2018-11-14 | 2021-11-09 | 旗舰先锋创新V股份有限公司 | 用于特定隔室货物递送的组合物和方法 |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| US20220136004A1 (en) * | 2019-01-11 | 2022-05-05 | Chan Zuckerberg Biohub, Inc. | Targeted In Vivo Genome Modification |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| WO2020197984A1 (en) | 2019-03-22 | 2020-10-01 | Albany Medical College | Methods for improving cognitive function |
| EP3963076A1 (en) * | 2019-05-02 | 2022-03-09 | Celyad | Cells with multiplexed inhibitory rna |
| US12552855B2 (en) * | 2019-05-08 | 2026-02-17 | Regeneron Pharmaceuticals, Inc. | CD33 targeted immunotherapies |
| US20220340927A1 (en) * | 2019-09-01 | 2022-10-27 | Exuma Biotech Corp. | Methods and compositions for the modification and delivery of lymphocytes |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| WO2021044439A1 (en) * | 2019-09-08 | 2021-03-11 | Immunoadaptive Cell Therapy Pvt Ltd. | Inducible cytokine signals & methods for immunotherapy |
| CA3154281A1 (en) * | 2019-10-16 | 2021-04-22 | Andrew Scharenberg | Retroviral vector for universal receptor therapy |
| CN112779223B (zh) * | 2019-11-08 | 2024-06-11 | 浙江煦顼技术有限公司 | 偶联嵌合抗原受体细胞及其用途 |
| EP4065157A1 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| AU2020395113A1 (en) * | 2019-12-02 | 2022-06-09 | Shape Therapeutics Inc. | Therapeutic editing |
| JP2023504884A (ja) * | 2019-12-05 | 2023-02-07 | ヴィセリックス・インコーポレーティッド | ユニバーサル細胞療法のための免疫逃避機構のモジュレーター |
| WO2021142376A1 (en) * | 2020-01-08 | 2021-07-15 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
| AU2021213735A1 (en) | 2020-01-30 | 2022-09-22 | Umoja Biopharma, Inc. | Bispecific transduction enhancer |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| CN115243713A (zh) * | 2020-03-05 | 2022-10-25 | 埃克苏马生物技术公司 | 用于递送修饰的淋巴细胞聚集体的方法和组合物 |
| KR20230010231A (ko) * | 2020-05-11 | 2023-01-18 | 아빈투스 바이오, 인코포레이티드 | 생체내 형질도입을 위한 벡터 및 방법 |
| CN112592408B (zh) * | 2020-07-20 | 2021-08-17 | 北京鼎成肽源生物技术有限公司 | 一种靶向c-Met的单链抗体、嵌合抗原受体、重组载体、CAR-T细胞及应用 |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| CN118064467A (zh) * | 2020-11-02 | 2024-05-24 | 上海医药集团生物治疗技术有限公司 | 两个或多个靶点嵌合抗原受体基因工程载体及其应用 |
| AU2022212952A1 (en) | 2021-01-27 | 2023-08-10 | Umoja Biopharma, Inc. | Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor |
| AU2022212090A1 (en) | 2021-01-28 | 2023-07-06 | Allogene Therapeutics, Inc. | Methods for transducing immune cells |
| WO2022187289A1 (en) | 2021-03-01 | 2022-09-09 | Exuma Biotech Corp. | Methods and compositions for the delivery of retroviral particles |
| WO2022216906A1 (en) * | 2021-04-08 | 2022-10-13 | The Scripps Research Institute | Novel therapies with engineered effector cells |
| KR20240028975A (ko) | 2021-04-08 | 2024-03-05 | 사나 바이오테크놀로지, 인크. | Cd8-특이적 항체 구조체들 및 이의 조성물 |
| TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| CN117813378A (zh) * | 2021-07-26 | 2024-04-02 | 乔治亚技术研究公司 | 用于通过免疫细胞展示进行体内蛋白酶谱分析的组合物和方法 |
| CN116143944B (zh) * | 2021-11-17 | 2026-03-20 | 上海君赛生物股份有限公司 | 含gpi锚定区的膜表面蛋白 |
| JP2024546145A (ja) * | 2021-12-22 | 2024-12-17 | クレ．エーアイ，インク． | 迅速ｔ－細胞製造 |
| EP4469586A1 (en) | 2022-03-01 | 2024-12-04 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
| CA3254198A1 (en) * | 2022-05-27 | 2023-11-30 | Kite Pharma, Inc. | Compositions and methods for preparing engineered lymphocytes for cell therapy |
| WO2024050138A2 (en) * | 2022-09-02 | 2024-03-07 | Myeloid Therapeutics, Inc. | Compositions for cell-specific expression and uses thereof |
| IL319793A (en) * | 2022-09-22 | 2025-05-01 | Myeloid Therapeutics Inc | Engineered chimeric fusion protein compositions and methods for using them |
| CN115807020A (zh) * | 2022-09-23 | 2023-03-17 | 卡瑞济(北京)生命科技有限公司 | 白介素15受体α装甲CAR-T细胞在降低白介素15诱导的细胞毒性中的用途 |
| CN116731974B (zh) * | 2023-05-23 | 2024-11-29 | 杭州荣谷生物科技有限公司 | 病毒的制备方法和应用 |
| WO2024259051A1 (en) * | 2023-06-14 | 2024-12-19 | The Children's Medical Center Corporation | Systems and methods for modifying a polynucleotide |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| FR2713657B1 (fr) * | 1993-12-13 | 1996-03-01 | Transgene Sa | Nouveaux vecteurs pour le traitement du sida. |
| KR100551104B1 (ko) | 1994-12-09 | 2006-02-09 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의 동정 |
| AUPR074500A0 (en) * | 2000-10-13 | 2000-11-09 | Monash University | Treatment of t cell disorders |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| EP1769078A1 (en) * | 2004-07-01 | 2007-04-04 | VIRxSYS Corporation | Vector packaging cell line |
| AU2005306801B2 (en) | 2004-11-08 | 2012-05-17 | The Regents Of The University Of Colorado | Structure-based compound design involving riboswitches |
| EP2164996A4 (en) * | 2007-05-29 | 2010-07-14 | Univ Yale | RIBOSWITCHES AND METHOD AND COMPOSITIONS FOR USE AND WITH RIBOSWITCHES |
| CN102369296A (zh) | 2009-03-09 | 2012-03-07 | 生物蛋白有限公司 | Mirac蛋白 |
| TR201904484T4 (tr) | 2009-11-03 | 2019-05-21 | Hope City | Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt). |
| CA2832569A1 (en) * | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| GB201107768D0 (en) * | 2011-05-10 | 2011-06-22 | Univ Manchester | Riboswitches |
| CN104011080B (zh) | 2011-12-22 | 2017-10-20 | 弗·哈夫曼-拉罗切有限公司 | 用于真核细胞的全长抗体展示系统及其用途 |
| CA2861491C (en) * | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| EP2820138B1 (en) * | 2012-02-29 | 2020-10-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Retroviral transduction using poloxamers |
| WO2014138306A1 (en) | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Engager cells for immunotherapy |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| KR20160010493A (ko) * | 2013-05-14 | 2016-01-27 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 접착제 조성물 |
| BR112016009465A8 (pt) | 2013-10-28 | 2018-01-30 | Univ Pittsburgh Commonwealth Sys Higher Education | vetor de hsv oncolítico. |
| WO2016016344A1 (en) | 2014-07-29 | 2016-02-04 | Cellectis | Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy |
| DK4074735T3 (da) * | 2014-08-28 | 2025-07-14 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| GB201503500D0 (en) * | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| HK1255161A1 (zh) * | 2015-07-15 | 2019-08-09 | Juno Therapeutics, Inc. | 用於过继性细胞治疗的工程细胞 |
| CA3030003A1 (en) * | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| KR102879522B1 (ko) * | 2017-03-03 | 2025-11-04 | 엑수마 바이오테크, 코포레이션 | 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물 |
-
2017
- 2017-03-19 CU CU2018000109A patent/CU24649B1/es unknown
- 2017-03-19 SG SG10202104509PA patent/SG10202104509PA/en unknown
- 2017-03-19 IL IL261713A patent/IL261713B2/en unknown
- 2017-03-19 SG SG11201807286WA patent/SG11201807286WA/en unknown
- 2017-03-19 WO PCT/US2017/023112 patent/WO2017165245A2/en not_active Ceased
- 2017-03-19 JP JP2018568183A patent/JP7108551B2/ja active Active
- 2017-03-19 AU AU2017236796A patent/AU2017236796B2/en active Active
- 2017-03-19 CN CN202310365875.0A patent/CN116426490A/zh active Pending
- 2017-03-19 RU RU2018136607A patent/RU2755059C2/ru active
- 2017-03-19 US US15/462,855 patent/US10596274B2/en active Active
- 2017-03-19 KR KR1020187029258A patent/KR102457098B1/ko active Active
- 2017-03-19 EP EP17714989.5A patent/EP3430136A2/en active Pending
- 2017-03-19 CA CA3017378A patent/CA3017378A1/en active Pending
- 2017-03-19 MX MX2018011345A patent/MX2018011345A/es unknown
- 2017-03-19 CN CN201780018352.1A patent/CN108884460B/zh active Active
-
2018
- 2018-09-18 MX MX2025000222A patent/MX2025000222A/es unknown
-
2021
- 2021-10-14 AU AU2021250935A patent/AU2021250935A1/en active Pending
-
2022
- 2022-04-05 JP JP2022062818A patent/JP7474281B2/ja active Active
-
2024
- 2024-04-12 JP JP2024064510A patent/JP2024086884A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019509063A5 (https=) | ||
| JP2018506983A5 (https=) | ||
| JP2023060000A (ja) | レトロウイルスおよびレンチウイルスベクター | |
| RU2018136607A (ru) | Способы и составы для производства лимфоцитов и их регулируемого увеличения | |
| US20240093232A1 (en) | Retroviral And Lentiviral Vectors | |
| CN110506060B (zh) | 嵌合分子及其用途 | |
| JP2023517940A5 (https=) | ||
| JP2020074776A5 (https=) | ||
| JP2017528158A5 (https=) | ||
| US10752668B2 (en) | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule | |
| JP2008538174A5 (https=) | ||
| JP2019512251A5 (https=) | ||
| JP2019150066A5 (https=) | ||
| JP2019514373A (ja) | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 | |
| JP2009201525A5 (https=) | ||
| JP2017537622A5 (https=) | ||
| JP2017532966A5 (https=) | ||
| JP2017506882A5 (https=) | ||
| EP4448775A1 (en) | Modified paramyxoviridae attachment glycoproteins | |
| WO2014016383A2 (en) | Glycoproteins for pseudotyping lentivectors | |
| EP4602174A1 (en) | Viral particles targeting hematopoietic stem cells | |
| US20260055146A1 (en) | Delivery of heterologous proteins | |
| Froelich et al. | Lentiviral vectors for immune cells targeting | |
| JP2012110290A5 (https=) | ||
| JP2025500338A5 (https=) |